Clinical correlation between effective anticoagulants and risk of stroke: Are we using evidence-based strategies?

Southern Medical Journal

Volumn 97, Issue 10, 2004, Pages 924-931

  Rahimi, Ali R ^a   Wrights, Bobby ^a   Akhondi, Hossein ^a   Richard, Christian M ^a  

^a MEMORIAL HEALTH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Atrial fibrillation; Primary prevention; Stroke; Thromboembolic event; Warfarin

Indexed keywords

ANTICOAGULANT AGENT; WARFARIN;

ADULT; AGED; ANTICOAGULANT THERAPY; CAUCASIAN; CEREBROVASCULAR ACCIDENT; CONTINUING EDUCATION; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORRELATION COEFFICIENT; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; EVIDENCE BASED MEDICINE; FEMALE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HUMAN; INTERNATIONAL STANDARD UNIT; MAJOR CLINICAL STUDY; MALE; NEGRO; PRESCRIPTION; PRIMARY PREVENTION; RETROSPECTIVE STUDY; REVIEW; STROKE;

ADULT; AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; CEREBROVASCULAR ACCIDENT; COMORBIDITY; EVIDENCE-BASED MEDICINE; FEMALE; GEORGIA; HUMANS; INTERNATIONAL NORMALIZED RATIO; LOGISTIC MODELS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SPECIALTIES, MEDICAL; WARFARIN;

EID: 6344233077     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.SMJ.0000129930.40928.3F     Document Type: Review

References (14)

1. Fintel, DJ, Hofmann, C. The AFP guide to preventing strokes and lowering health risks in patients with atrial fibrillation [Monograph]. Lisle, Illinois: Northwestern University Medical School and Illinois Academy of Family Physicians; 2000.
2. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter, stroke prevention in patients with non-valvular atrial fibrillation. Neurology 1998;51:671-673.
3. Management of Chronic Atrial Fibrillation [Monograph]. Am Fam Physician, Fall 1993;1-23.
4. Laupacin A, Albers G, Dalen J, et al. Antithrombotic therapy in atrial fibrillation. Chest 1998;114:579S-589S.
5. Lightowlers S, McGuire A. Cost-effectiveness of anticoagulation in nonrheumatic atrial fibrillation in primary prevention of ischemic stroke. Stroke 1998;29:1827-1832.
6. Hort RG, Benarente O, McBride R, et al. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999;131:492-501.
7. Hylek EA, Skates SJ, Sheehan MA, et al. An analysis of the lowest effective intensity of prophylactic anticoagulation in patients with nonrheumatic atrial fibrillation. N Engl J Med 1996;335:540-546.
8. The Boston area anticoagulation trial for atrial fibrillation investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med 1990;323:1505-1511.
9. Stroke prevention in atrial fibrillation study: final results. Circulation 1991;84:527-539.
10. The European atrial fibrillation trial study group. Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. N Engl J Med 1995;333:5-10.
11. Gates JA, Wood AJJ. Drug therapy. N Engl J Med 1991;324:26:1865-1874.
12. Peterson P, Boysen G, Godtfredsen J, et al. Placebo controlled, randomized trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK study. Lancet 1989;1:175-179.
13. Sudlow M, Thomson R, Thwartes B, et al. Prevalence of atrial fibrillation and eligibility for anticoagulants in the community. Lancet 1998; 352:1167-1171.
14. Proceedings of the American College of Chest Physicians 5th Consensus on Antithrombotic Therapy. 1998. Chest 1998;114(5 Suppl):439S-769S.